Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Profit After Tax (2016 - 2025)

Tg Therapeutics has reported Profit After Tax over the past 10 years, most recently at $23.0 million for Q4 2025.

  • Quarterly results put Profit After Tax at $23.0 million for Q4 2025, down 1.26% from a year ago — trailing twelve months through Dec 2025 was $447.2 million (up 1812.41% YoY), and the annual figure for FY2025 was $447.2 million, up 1812.41%.
  • Profit After Tax for Q4 2025 was $23.0 million at Tg Therapeutics, down from $390.9 million in the prior quarter.
  • Over the last five years, Profit After Tax for TGTX hit a ceiling of $390.9 million in Q3 2025 and a floor of -$93.3 million in Q4 2021.
  • Median Profit After Tax over the past 5 years was -$25.1 million (2022), compared with a mean of -$4.4 million.
  • Biggest five-year swings in Profit After Tax: tumbled 96.59% in 2024 and later surged 9974.61% in 2025.
  • Tg Therapeutics' Profit After Tax stood at -$93.3 million in 2021, then increased by 15.93% to -$78.5 million in 2022, then soared by 81.63% to -$14.4 million in 2023, then skyrocketed by 261.84% to $23.3 million in 2024, then decreased by 1.26% to $23.0 million in 2025.
  • The last three reported values for Profit After Tax were $23.0 million (Q4 2025), $390.9 million (Q3 2025), and $28.2 million (Q2 2025) per Business Quant data.